Tonix Pharmaceuticals
TNXP
26 hedge funds and large institutions have $8.53M invested in Tonix Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 19 closing their positions.
1,000% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 1
76% more capital invested
Capital invested by funds: $4.85M → $8.53M (+$3.68M)
7.49% more ownership
Funds ownership: 0.08% → 7.56% (+7.5%)
19% less funds holding
Funds holding: 32 → 26 (-6)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.85M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$858K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$692K |
| 4 |
Millennium Management
New York
|
+$690K |
| 5 |
HF
HRT Financial
New York
|
+$551K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$548K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$526K |
| 3 |
PI
PFG Investments
Woodbury,
New York
|
-$71.9K |
| 4 |
Two Sigma Investments
New York
|
-$66.2K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$40K |
TNXP Hedge Fund Activity: Q1 2025 in Review
26 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2025, worth a combined $8.53M — up 76% from $4.85M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of TNXP and 13 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, opening a new position worth an estimated $1.85M. The largest seller was Jane Street, exiting entirely with an estimated $548K sold.
- 26 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2025, down from 32 in Q4 2024.
- Funds reported $8.53M of Tonix Pharmaceuticals stock for Q1 2025, up 76% quarter-over-quarter.
- 13 funds opened new Tonix Pharmaceuticals positions in Q1 2025 and 19 closed out, a net change of -6 holders.
- The largest Tonix Pharmaceuticals buyer in Q1 2025 was Vanguard Group, an estimated $1.85M added.
- The largest Tonix Pharmaceuticals seller in Q1 2025 was Jane Street, an estimated $548K sold.
Based on aggregated 13F filings for Q1 2025.